Scott Lish Sells 23,183 Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) COO Scott Lish sold 23,183 shares of the company’s stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $12.03, for a total transaction of $278,891.49. Following the sale, the chief operating officer now directly owns 844,494 shares in the company, valued at approximately $10,159,262.82. The trade was a 2.67 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Scott Lish also recently made the following trade(s):

• On Thursday, February 6th, Scott Lish sold 27,453 shares of Alphatec stock. The shares were sold at an average price of $11.49, for a total transaction of $315,434.97.

Alphatec Stock Up 3.4 %

Alphatec stock traded up $0.41 during mid-day trading on Friday, hitting $12.53. The company had a trading volume of 3,473,121 shares, compared to its average volume of 1,786,753. The stock has a market cap of $1.78 billion, a price-to-earnings ratio of -9.79 and a beta of 1.43. Alphatec Holdings, Inc. has a 1 year low of $4.88 and a 1 year high of $14.88. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21. The business has a fifty day moving average of $10.63 and a 200 day moving average of $8.37.

Alphatec (NASDAQ:ATEC) last issued its quarterly earnings results on Wednesday, February 26th. The medical technology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.04). Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. The company had revenue of $176.79 million for the quarter, compared to analyst estimates of $172.74 million. On average, sell-side analysts expect that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently commented on ATEC. Needham & Company LLC reaffirmed a “buy” rating and issued a $16.00 price target on shares of Alphatec in a research note on Thursday. HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of Alphatec in a report on Tuesday, January 14th. Barclays raised their price target on shares of Alphatec from $20.00 to $21.00 and gave the company an “overweight” rating in a report on Wednesday, January 22nd. Finally, Piper Sandler increased their price objective on shares of Alphatec from $12.00 to $13.00 and gave the company an “overweight” rating in a research report on Thursday. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $17.67.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Comerica Bank raised its stake in shares of Alphatec by 66.8% during the 4th quarter. Comerica Bank now owns 3,116 shares of the medical technology company’s stock worth $29,000 after buying an additional 1,248 shares during the last quarter. R Squared Ltd purchased a new stake in Alphatec during the 4th quarter worth about $29,000. Nisa Investment Advisors LLC increased its position in Alphatec by 973.3% during the 4th quarter. Nisa Investment Advisors LLC now owns 4,669 shares of the medical technology company’s stock worth $43,000 after purchasing an additional 4,234 shares in the last quarter. Quarry LP increased its position in Alphatec by 79.2% during the 4th quarter. Quarry LP now owns 5,374 shares of the medical technology company’s stock worth $49,000 after purchasing an additional 2,375 shares in the last quarter. Finally, Newton One Investments LLC purchased a new stake in Alphatec during the 4th quarter worth about $50,000. Institutional investors and hedge funds own 66.35% of the company’s stock.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.